WHO Sounds Warning Over Critical Scarcity of Weight-Loss Jabs

Less than one in 10 people eligible to benefit from obesity jabs including Wegovy can access them, states the WHO as it publishes its first recommendations on the therapies.

With more than one billion individuals worldwide now living with obesity, it is calling for broader and more equitable access to GLP-1 medication.

Based on projections, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.

"Our new guidelines affirms that obesity is a lifelong illness that can be managed with holistic and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and logistical bottlenecks are major hurdles to widespread availability to the treatments that can help people shift considerable body mass, explains the body.

Skinny Jab Shortage

Even in the current most favorable case, the supply of these medications might only reach about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The recommendation urges governments and firms to widen availability, through strategies including voluntary licensing.

A patent on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.

How Obesity Drugs Operate

These medications replicate a biological compound to slow digestion, reduce hunger and boost feelings of fullness so people reduce food intake.

Individuals typically begin shedding pounds within a few weeks of beginning the regular doses.

Research points to users may see weight return after a year of halting the medication, because their normal hunger return.

To be carrying excess weight elevates your chance for experiencing health problems, such as diabetes, heart disease, stroke, and certain cancers.

Excess weight concerns individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.